TSX:APS - CA03835T4081 - Common Stock
The current stock price of APS.CA is 1.65 CAD. In the past month the price decreased by -4.62%. In the past year, price decreased by -89.42%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EDT.CA | SPECTRAL MEDICAL INC | N/A | 465.89M | ||
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 345.09M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 265.03M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 208.29M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 110.75M | ||
WLLW.CA | WILLOW BIOSCIENCES INC | N/A | 97.56M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 87.58M | ||
BLU.CA | BLUENERGIES LTD | N/A | 84.96M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 66.23M | ||
NRX.CA | NUREXONE BIOLOGIC INC | N/A | 64.81M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 17.54 | 62.52M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 51.14M |
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
APTOSE BIOSCIENCES INC
66 Wellington Street West, Suite 5300,, TD Bank Tower Box 48
TORONTO ONTARIO M2J 4R3 CA
CEO: William G. Rice
Employees: 13
Phone: 18589262730
The current stock price of APS.CA is 1.65 CAD. The price increased by 0.61% in the last trading session.
The exchange symbol of APTOSE BIOSCIENCES INC is APS and it is listed on the Toronto Stock Exchange exchange.
APS.CA stock is listed on the Toronto Stock Exchange exchange.
7 analysts have analysed APS.CA and the average price target is 136.76 CAD. This implies a price increase of 8188.55% is expected in the next year compared to the current price of 1.65. Check the APTOSE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
APTOSE BIOSCIENCES INC (APS.CA) has a market capitalization of 4.21M CAD. This makes APS.CA a Nano Cap stock.
APTOSE BIOSCIENCES INC (APS.CA) currently has 13 employees.
APTOSE BIOSCIENCES INC (APS.CA) has a support level at 1.58 and a resistance level at 1.73. Check the full technical report for a detailed analysis of APS.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
APS.CA does not pay a dividend.
APTOSE BIOSCIENCES INC (APS.CA) will report earnings on 2025-11-06, after the market close.
APTOSE BIOSCIENCES INC (APS.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-65.17).
ChartMill assigns a technical rating of 1 / 10 to APS.CA. When comparing the yearly performance of all stocks, APS.CA is a bad performer in the overall market: 98.95% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to APS.CA. Both the profitability and financial health of APS.CA have multiple concerns.
Over the last trailing twelve months APS.CA reported a non-GAAP Earnings per Share(EPS) of -65.17. The EPS increased by 79.6% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -327.57% | ||
ROE | N/A | ||
Debt/Equity | N/A |
7 analysts have analysed APS.CA and the average price target is 136.76 CAD. This implies a price increase of 8188.55% is expected in the next year compared to the current price of 1.65.